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To examine the significance of the methylation level of the p53 target and tumour suppressor genes apoptotic protease activating
factor-1 (APAF-1) and death-associated protein kinase-1 (DAPK-1) in 80 microdissected tumour samples from transitional cell
carcinoma (TCC) of the bladder and 80 tumour samples from clear-cell renal cell carcinoma (RCC) as well as from non-tumourous
bladder and kidney tissue. Growth-inhibitory effects of the demethylating agents 5-Aza-20-deoxycytidine (5-Aza-CdR) and zebularine
were investigated in TCC and RCC cell lines. The methylation frequency of APAF-1 (DAPK-1) was 100% (77%) in TCC and 100%
(33%) in RCC. The methylation levels of APAF-1 could differentiate between the individual tumour stages in TCC as well as in RCC.
The APAF-1 methylation levels in RCC were significantly higher in tumours larger than 4cm and in high-grade tumours. The
methylation frequencies in normal tissue for APAF-1 (DAPK-1) were 11% (8%) in bladder tissue and 9% (5%) in kidney tissue. The
growth-inhibitory effect of the demethylating agents in TCC (RT4, T24) and RCC (A498, ClearCa-5) cell lines resulted in a 17–132%
prolongation of the doubling time (DT). In RCC cell lines, zebularine was superior to 5-Aza-CdR in achieving a DT prolongation.
Quantitative real time RT-PCR detected a re-expression of mRNA transcripts of APAF-1 or DAPK-1. In conclusion, demethylating
agents effectively retard growth of TCC and RCC cell lines. Methylation level analysis of specific genes has the potential for further
tumour characterisation in TCC and RCC.
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Bladder and kidney cancers are among the most frequent
urogenital malignancies with an annual incidence of 91000 for
bladder and 37000 for kidney cancer in the European Union
(Boyle and Ferlay, 2005). The majority of bladder tumours (70%)
appear to be superficial, but a number of them will eventually
recur and some will progress to higher stages. Once the tumour
becomes muscle-invasive, radical surgical measures like cystec-
tomy are recommended. Systemic platinum-based chemotherapy
can be applied in the adjuvant or neoadjuvant setting of locally
advanced or node-positive bladder cancer or in cases of metastatic
disease (Garcia and Dreicer, 2005). Renal cell carcinoma (RCC) is
not sensitive to chemo- or even radiotherapy and immunother-
apeutic approaches using cytokines are limited in effectivity and in
the survival advantage they provide in metastatic disease (Amato,
2000). Recently, multikinase inhibitors, such as sunitinib or
sorafenib, have demonstrated efficacy and disease-stabilising
activity as single agents in second-line therapy for patients with
cytokine-refractory metastatic clear-cell RCC (Motzer et al, 2006;
Ratain et al, 2006).
One mechanism in the multistep model of tumorigenesis is the
promoter methylation of specific tumour suppressor genes. If
methylation occurs within the promoter region of a suppressor
gene, epigenetic silencing of this gene may lead to functional
inactivation, a mechanism reported for various tumour entities
(Jones and Baylin, 2002).
If the methylation of a tumour suppressor gene is relevant for
gene silencing, the reversal of methylation by demethylating agents
could lead to reactivation of the gene. Unfortunately, the
applicability of the commonly used 5-Aza-20-deoxycytidine (5-
Aza-CdR) is hampered by its high toxicity and instability in
physiological solutions (Momparler, 1985; Bender et al, 1998).
However, the recently identified zebularine is less toxic and more
stable and can be administered orally (Kim et al, 1986; Cheng et al,
2003).
Deregulation of apoptosis leads to irregular cell survival and has
been implicated in the development of cancer. Functional loss of
the proapoptotic p53 gene has been recognised as a common event
in a wide range of cancer types (Levine et al, 1991). However, only
a few mediators of apoptosis, especially the p53 target genes, have
been shown to relate gene inactivation with tumour progression
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s(Feinstein et al, 1995; Jia et al, 2001; Soengas et al, 2001; Tada et al,
2002).
The aim of this study was to further investigate the occurrence
and relevance of promoter methylation of the p53 target genes
death-associated protein kinase-1 (DAPK-1) and apoptotic pro-
tease activating factor-1 (APAF-1) in relation to different stages
of tumour progression in transitional cell carcinoma (TCC) and
RCC. In addition, in vitro experiments were conducted with the
demethylating agents 5-Aza-CdR and zebularine to investigate
their global growth inhibitory effects in different bladder (RT4,
T24) and kidney cancer (A498, ClearCa-5) cell lines with p53 wild-
type (RT4, A498) and p53 mutated (T24, ClearCa-5) status.
The two genes were assessed for their methylation status in
microdissected tissue by quantitative real-time methylation-
specific polymerase chain reaction (PCR) (MSP), applying the
normalised index of methylation (NIM). Quantitative real-time
RT-PCR was used to investigate the effects of the demethylating
agents on subsequent mRNA re-expression following treatment
with 5-Aza-CdR or zebularine.
MATERIALS AND METHODS
This study included 80 patients (35 women and 45 men) with
superficial and muscle-invasive bladder cancer disease and 80
(24 women and 56 men) who had primary clear-cell RCC and
underwent radical nephrectomy. All patients were treated at the
Department of Urology between January 1997 and December 2000.
The bladder cancer patients were submitted to transurethral
resection of the bladder for superficial disease and to radical
cystectomy after initial transurethral resection for muscle-invasive
disease. Normal transitional cell tissue was obtained from 20
patients who underwent open surgery for benign prostatic
hyperplasia. Normal kidney specimens were obtained by ne-
phrectomy for a nonmalignant tumour disease like hydronephro-
sis in 10 cases and by taking nonmalignant kidney tissue distant
from the tumour in 10 other cases. The tissue samples were shock-
frozen immediately after surgical resection of the tumour or
normal tissue and stored in liquid nitrogen at  801C. Before
further processing, samples were serially sectioned, stained with
hematoxylin-eosin and examined by a uropathologist (JK) to
ensure that slices used for subsequent DNA extraction mainly
contained malignant tissue of the respective tumour. The areas
with the highest neoplastic cell content (480%) were selected and
microdissected with a sterile needle under microscopic control.
The TNM classification of the International Union against Cancer
was used for histopathological staging and grading (1997). All
patients signed a consent form approved by the Committee on
Human Rights in Research at our institution.
DNA isolation and preparation
After dissection, DNA was isolated from the tissue using the
BioRobot
s EZ1 workstation according to the manufacturer’s
instructions (Qiagen, Hilden, Germany). The DNA concentration
was determined by spectrophotometry, and its integrity was
checked by 1.5% gel electrophoresis.
Bisulfite modification and MSP
A total of 2mg of genomic DNA from cell line and tissue samples
was subjected to bisulfite modification using the MethylEasyt
DNA Bisulfite Modification Kit (Human Genetic Signatures Pty
Ltd, Macquarie Park, Australia) according to the manufacturer’s
instructions. Methylation analysis was performed by fluorescence-
based real-time PCR using Taqman hybridisation probes with
the Light Cycler Instrument (Roche, Germany). Each primer set
contained at least two CpG sites and was located within the
promoter region of the gene. Polymerase chain reaction consisted
of initial denaturation for 10min at 951C, followed by 50 cycles
with individual annealing temperatures and times (APAF-1 601C,
20s; DAPK-1 581C, MyoD 591C, 15s) and final elongation for 40s
at 721C. Polymerase chain reaction was also performed for non-
CpG-containing regions of MyoD, which served as a control gene
(sense: 50-CCA ACT CCA ATT CCC CTC TCT AT, antisense 50-
TGA TTA ATT TAG ATT GGG TTT AGA GAA GGA, Taqman
6FAM-50-TCC CTT CCT ATT CCT AAA TCC AAC CTA AAT ACC
TCC XT–PH; acc. no. AF027148) (Jeronimo et al, 2001). The
primer sequences for APAF-1 were (sense: 50-TTT CGG GTA AAA
GGG ATA GAA TTA GA, antisense 50-AAA AAT CTT CCC GAC
CTA TAA CGC, Taqman 6FAM-50-ATA CCG CTA CGA CAC CTC
AAA TCT TCG C–TMR; acc. no. AB070829). For DAPK-1 they were
(sense: 50-TCG TCG TCG TTT CGG TTA GTT, antisense 50-TCC
CTC CGA AAC GCT ATC G, Taqman 6FAM-50-CGA CCA TAA
ACG CCA ACG CCG–TMR; acc. no. NM_004938). For relative
quantification, standard curves were generated separately for
APAF-1, DAPK-1 and MYOD1 from serial dilutions of bisulfite-
modified CpGenomet Universal Methylated DNA (Chemicon
International, Temecula CA, USA), and standards were included
in each PCR run. The NIM was calculated for each sample as
described elsewhere (Gonzalgo et al, 2004).
RNA isolation, preparation and real-time RT-PCR
Total RNA was extracted from cell lines and human testicular
samples using RNeasy
s Mini Kit (Qiagen GmbH, Hilden,
Germany), according to the manufacturer’s instructions. RNA
concentration was determined using NanoDrop ND-1000 and RNA
integrity was approved using the Agilent Bioanalyzer 2100 (Agilent
Technologies, Waldbronn, Germany). Quantitative real-time RT-
PCR for APAF-1 and DAPK-1 mRNA (genbank acc. no. AF013263
and NM_004938) was performed on LightCycler
s system. In a
one-step RT-PCR reaction, 250ng of total RNA were subjected to
cDNA synthesis and subsequently amplified during 35 PCR cycles
(reverse transcription: 10min at 551C, reverse transcriptase
inactivation: 30s at 951C, cycles: 0.5s at 951C, 15s at 601C, 20s
at 721C) using LightCycler
s RNA Amplification Kit Hybridisation
Probe (Roche Diagnostics GmbH, Penzberg, Germany). The
specific primers used for mRNA amplification were as follows:
APAF-1 forward: 50- GCT CTC CAA ATT GAA AGG TGA AC-30;
reverse: S50- ACT GAA ACC CAA TGC ACT CC-30; FL-probe: 50-
AAA AGG GAA TGA TCT CTA ACA GCT TCT GCA-FL; LC-probe:
50-LC Red640: CTA ATA CAG ACT TCC CAC AGC CTG CCA-PH
and DAPK-1 forward: 50-AAA ACC ACC CTT GTA GAA TCT CTC
AA-30; reverse: S50-GTT CTC GCA GCC TGG GTA C-30; FL-probe:
50-CTT TTT CAG AAG GCG TCG GCC C-FL; LC-probe: 50-LC
Red640: GAC TGT CTT CCA CCA ACT CCA GCA GGT T-PH. In
parallel, RT-PCR detecting the reference gene porphobilinogen
deaminase (PBGD) was performed for each sample using the
LightCyler
s h-PBGD Housekeeping Gene Set according to the
manufacturer’s recommendations (Roche Diagnostics, Mannheim,
Germany). For relative quantification, standards were established
from serial dilutions of APAF-1, DAPK-1 and PBGD cDNA
templates, generated separately and included in each run. Relative
gene expression (RGE) was calculated for each sample, as the ratio
of APAF-1 or DAPK-1 copy number (target gene) to PBGD mRNA
copy number multiplied by 100, thus normalising APAF-1 or
DAPK-1 mRNA expression for sample to sample differences in
RNA input, quality and PCR efficiency (Karge et al, 1998).
Cell culture and drug treatments
The human bladder carcinoma cell lines RT4 and T24 were grown
in RPMI 1640 medium supplemented with 10% foetal bovine
serum, sodium pyruvate and L-glutamine (Rigby and Frankis,
1970). The RCC line A498 (American Type Culture Collection) was
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scultured in RPMI 1640 medium, supplemented as described above
(Giard et al, 1973). The RCC cell line ClearCa-5 was derived from a
typical representative of the clear-cell type of RCC (Wethkamp
et al, 2006). Initial drug treatment was started 24h after seeding.
RT4, T24, A498 and ClearCa-5 cells were plated (3 10
5cells
100-mm
 1 dish) for continuous drug treatment with zebularine to
a final concentration of 10
 4 M. Treatment was started when cells
were in logarithmic growth. The medium was changed every 3 days
along with fresh zebularine treatment. RT4, T24, A498 and
ClearCa-5 cells were plated for sequential drug treatment with
5-Aza-CdR (3 10
5cells100-mm
 1 dish). Cells were in logarithmic
growth when 5-Aza-CdR was added after 24h to a final
concentration of 2 10
 6 M. After 24h, the medium was changed
again, and 5-Aza-CdR was again added for 24h to a final
concentration of 2 10
 6 M. Then the medium was changed and
cells were grown in fresh untreated medium. The concentrations of
5-Aza-CdR and zebularine were chosen according to previous
reports (Cheng et al, 2004a).
The control group comprised cells grown under the same
conditions but treated with phosphate-buffered saline (PBS). DNA
and RNA were harvested after 7 days for methylation and RT-PCR
analyses, respectively. All cells were maintained at 371Ci na
humified atmosphere with 5% CO2 in air and cultured in RPMI
1640 (Biochrom AG, Berlin, Germany). 5-Aza-CdR (Sigma-Aldrich,
A3656) was stored as a 2mM and zebularine (Sigma-Aldrich,
Z4775) as a 10mM stock solution dissolved in PBS.
Determination of population doublings and cell growth
Cells were counted with a Z1 Coulter particle counter (Beckman
Coulter Corporation, Hialeah, Fl, USA) on the seventh day after the
initial treatment. Untreated cells were analysed under similar
conditions for control purposes. Each experiment was repeated
four times. Doubling times (DT) were calculated 72, 120 and 168h
after treatment according to the following formula: DT¼timeX/
[log(nX/n0)/log2] with nX and n0 being the cell count at times X
and 0 (Kraemer et al, 2003).
Statistical analysis
Two-tailed statistical analysis was performed using SPSS computer
software (Version 12, SPSS Inc, Chicago, IL, USA). The Mann–
Whitney U-test was used to statistically evaluate the methylation
level of the individual genes in relation to the tumour stage and
grade. The paired student’s t-test was used for evaluation of mRNA
expression levels in the in vitro studies. For the comparison of cell
DTs, statistical analysis was carried out using the Wilcoxon pair-
difference test. All P-values o0.05 were considered statistically
significant.
RESULTS
This study included 80 patients with TCC of the bladder: 20 pTa
tumours, 30 pT1 tumours and 30XpT2 tumours. Transitional cell
carcinoma was low- or intermediate-grade (G1/2) in 24 patients
and high-grade (G3) in 56. Twelve patients with superficial pT1 G3
tumours had received BCG intravesical instillation therapy, and 16
patients with muscle-invasive bladder carcinoma had undergone
cisplatin-based chemotherapy. In a control group, the methylation
status of normal urothelium was measured in 20 patients without
malignant disease. All 80 patients in the group with RCC had clear-
cell tumours. Tumours were grouped as pT1 in 37 patients, pT2 in
21 and pT3 in 22. Tumours were G1/2 in 30 patients and G3 in 50.
There were 61 (76%) node-negative and 19 (24%) node-positive
tumours.
In the patient group with TCC, APAF-1 was found to be
methylated in all samples investigated, corresponding to a
methylation frequency of 100%. The methylation frequency of
DAPK-1 was 80% (16 out of 20) in pTa, 80% (24 out of 30) in pT1
and 70% (14 out of 20) in muscle invasive XpT2 tumour disease.
The median NIM levels for APAF-1 (DAPK-1) were 22% (31%) in
the pTa group, 60% (23%) in the pT1 group, and 78% (16%) in the
XpT2 group. When the tumours were grouped according to their
differentiation grade, the median NIM was 20% (53.4%) for APAF-
1 in the G1/2 (G3) group and 34.1% (3.6%) for DAPK-1 in the pTa
tumours. In the G1/2 (G3) group of pT1 tumours, the median NIM
was 53.5% (71%) for APAF-1 and 18.3% (24%) for DAPK-1. For
the muscle-invasive tumour group (XpT2, only G3 tumours), the
median NIM levels were 97.5% for APAF-1 and 15.8% for DAPK-1.
Apoptotic activating factor protein-1 methylation levels were able
to differentiate G3 tumours from pTa G1/2 tumours (P¼0.002)
but not from pT1 G1/2 tumours (P¼0.4). The APAF-1 NIM levels
could also differentiate between the individual tumour stages
(Po0.001). This was not the case for DAPK-1 methylation levels.
Table 1 gives further details on the median NIM levels.
In the patient group with RCC, the methylation frequency was
100% for APAF-1 irrespective of the tumour stage. Death-
associated protein kinase-1 was found to be methylated in 35%
(13 out of 37) of the pT1, 33% (seven out of 21) of the pT2, and
32% (seven out of 22) of the XpT3 tumours. Comparing the
median NIM levels of APAF-1 (DAPK-1) revealed a range
extending from 41.5% (17.4%) for pT1 to 58% (10.8%) for pT2
and 66% (19.3%) for XpT3 tumours. When the NIM levels were
compared according to the specific tumour grade of G1/2 or G3,
the median NIM levels for APAF-1 in G1/2 (G3) tumours were 34%
(51%) in pT1, 55% (58%) in pT2, and 72% (66%) in XpT3
tumours. The median NIM levels for DAPK-1 in G1/2 (G3)
tumours were 3% (0%) in pT1, 1% (7%) in pT2, and 0% (13%) in
XpT3 tumours. A trend towards a statistically significant
correlation was detected by comparing the median NIM levels of
APAF-1 and the different tumour stages (P¼0.06 and 0.05). The
NIM levels could not distinguish between the different tumour
grades. Table 2 gives more details.
Table 1 Percentage of methylation (NIM) and tumour stage/grade in
TCC
APAF-1 DAPK-1
G1/2 G3 P-value G1/2 G3 P-value
pTa
Median 20 53.4 34.1 3.6
Mean 22.7 49.6 37.2 17.6
STD 14.7 17.8 37.1 23.5




Median 53.5 71 18.3 24
Mean 62.8 66.4 27.4 41.3
STD 29.7 19.4 29.1 47.9








NIM¼normalised index of methylation; n.o.¼not observed; STD¼standard
deviation; TCC¼transitional cell carcinoma. *G1/2 vs G3 tumours. **pTa vs pT1
tumours. ***pT1 vs XpT2 tumours. Normal bladder tissue (n¼20): APAF-1 median
(0%), mean (7%), STD (17.3%)/DAPK-1 median (0%), mean (5%), STD (15.5%).
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sTo exclude a potential bias through age dependency and the
methylation level, the TCC and RCC groups were divided
according to the median age of the different cohorts, which was
72711.8 years in the TCC group and 65712.2 years in the RCC
group. Transitional cell carcinoma patients had median NIM levels
of 58% in the younger group and 65% in the older group for APAF-
1, the corresponding levels being 16 and 10%, respectively for
DAPK-1 (P¼0.4 and¼0.8). Renal cell carcinoma patients had
median NIM levels of 51% in the younger group and 53% in the
older group for APAF-1, the corresponding levels being 2 and 2%,
respectively for DAPK-1. A significant correlation was not detected
(P¼0.4 and 0.6).
The median NIM levels in the patient group with RCC were
compared between larger (X4cm) or node positive tumours and
smaller (o4cm) or node negative tumours. The median methyla-
tion levels for APAF-1 were 51% in node-negative tumours and
58% in node-positive tumours, the corresponding NIM levels for
DAPK-1 being 2 and 9%, respectively. A statistically significant
correlation was not detected (P¼0.09 and 0.26). The median NIM
levels for APAF-1 were 42% in smaller tumours and 60% in larger
ones; the corresponding levels for DAPK-1 were 2 and 3%,
respectively. A significant correlation was detected for the
methylation levels of APAF-1 (P¼0.008) but not for those of
DAPK-1 (P¼0.8).
Comparing RCC specimens according to their differentiation
grade revealed a correlation between higher (G1/2) and lower (G3)
differentiation; APAF-1 methylation levels compared as median
NIM levels were 41% for high-grade and 55% for low-grade
tumours (P¼0.05).
Finally, the methylation frequency and methylation levels were
analysed in normal tissue and methylation frequencies were 11%
for APAF-1 and 8% for DAPK-1 in bladder tissue and correspond-
ing frequencies of 9 and 5%, respectively in kidney tissue. The
median NIM levels were 0% for APAF-1 and 0% for DAPK-1 in
bladder tissue and 0 and 0%, respectively in kidney tissue (further
details see Tables 1 and 2). Also, a dependency between the APAF-1
and DAPK-1 methylation levels and the age of the patients was
not observed. Median age was 7375.3 years in the bladder tissue
group and 6776.7 years in the kidney tissue group.
Continuous zebularine or sequential 5-Aza-CdR treatment was
applied in two bladder cancer cell lines (RT4, T24) and two RCC
cell lines (A498, ClearCa-5). In the bladder cancer cell lines, 5-Aza-
CdR treatment retarded the growth of all cell lines investigated.
This was demonstrated by a significant increase in DT starting 5
days after the first exposure. Continuous zebularine treatment also
retarded the growth of both cell lines; a significant influence was
reflected in the prolonged DT found 5 and 7 days after the initial
treatment in T24 and RT4, respectively. In both RCC cell lines,
5-Aza-CdR as well as zebularine caused significant growth
inhibition, which became apparent on the fifth day after the initial
treatment (Table 3).
Treatment with 5-Aza-CdR (zebularine) decreased the median
NIM level of APAF-1 from 144 to 43% (73%) in RT4 and from 138
to 38% (37%) in T24. A comparable effect was observed in the RCC
cell lines, where the NIM level of APAF-1 decreased from 178 to
45% (39%) after treatment with 5-Aza-CdR (zebularine) in A498
and from 149 to 37% (31%) in the ClearCa-5 cell line. Methylation
of the DAPK-1 gene promoter was not observed in any of the four
untreated or treated cell lines investigated. The occurrence of NIM
levels higher than 100% is attributed to aneuploidy at the gene
locus of interest (Friedrich et al, 2004).
Quantitative real time RT-PCR was performed to determine
whether the observed demethylation effect correlated with an
induction of mRNA expression. Apoptotic activating factor
protein-1 mRNA expression was detectable in all untreated,
methylated control cell lines. After treatment with 5-Aza-CdR the
mRNA transcripts of APAF-1 were significantly upregulated in all
of the four cell lines. The increase of the median RGE units
observed was between 1.5 (ClearCa-5) and 5.4 (RT4)-fold.
Exposition to 5-Aza-CdR led to an increase of mRNA expression
(in RGEs) of DAPK-1 that was between 1.7-fold (ClearCa-5) and
11.6-fold (RT4) as compard to the RGEs in the corresponding
untreated cell line. Interestingly, the A498 RCC cell line showed a
significant decrease of mRNA expression from a median RGE of
60–29 arbitrary units.
After zebularine treatment, a significant upregulation of APAF-1
mRNA expression was observed in the p53 mutated cell lines
ClearCa-5 and T24 only, but not in the p53 wild-type cell lines
A498 and RT4. Death-associated protein kinase-1 mRNA expres-
sion was – as shown for APAF-1 mRNA expression – increased in
Table 2 Percentage of methylation (NIM) and tumour stage/grade in
RCC
APAF-1 DAPK-1
G1/2 G3 P-value G1/2 G3 P-value
pT1
Median 34 51 3 0
Mean 43.6 44.7 25.6 2.9
STD 20.9 22.2 39.9 7.9




Median 55 58 1 7
Mean 52 56.3 2.3 12.8
STD 26.9 23.5 3.3 19.6




Median 72 66 01 3
Mean 69.3 63.4 0.2 22.6
STD 26.1 14.3 0.5 24.3
n 22 0 22 0
P-value 0.7* 0.07*
NIM¼normalised index of methylation; RCC¼renal cell carcinoma. *G1/2 vs G3
tumours. ** pT1 vs pT2 tumours. *** pT2 vs XpT3 tumours. Normal kidney tissue
(n¼20): APAF-1 median (0%), mean (1.5%), STD (5%)/DAPK-1 median (0%), mean
(3%), STD (10.2%).
Table 3 DT in hours and prolongation in percent after treatment with
PBS, 5-AZA-CdR (2 10
 6 M) and zebularine (10
 4 M) at various time
points (TCC cell lines RT4, T24; RCC cell lines A498, CCa-5)
PBS 5-AZA ZEB
DT after DT after DT after
72h 120h 168h 72h 120h 168h 72h 120h 168h
RT4 79.1 75.7 79.4 77.6 83.2* 129.1* 75.4 75.1 88.6*
Percentage  4.3 +0.4 +7.3 +66.4  0.05 +17.5
T24 19.4 19.5 20.2 19.3 25.5* 34.7* 19.1 22.9* 34.3*
Percentage +0.5 +4.1 +32.1 +79.8 +19.9 +79.6
A498 64.7 65.8 62.9 62.5 71.3* 76.2* 61.5 65.8* 95.1*
Percentage +2.3  2.1 +14.1 +21.9 +6.9 +54.6
CCa-5 52.7 51.6 57.4 50.6 54.8* 104.2* 53.1 55.6* 123.1*
Percentage  2.1 +8.9 +8.3 +105.9 +4.7 +131.8
5-AZA-CdR¼5-AZA-20-deoxycytidine; DT¼doubling time; PBS¼phosphate-
buffered saline; ZEB¼zebularine. *¼P-value o0.05 (Wilcoxon pair difference test).
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sthe p53-mutated cell lines ClearCa-5 and T24 but remained
relatively unchanged in A498 and RT4. For more details see
Table 4.
DISCUSSION
Recent publications have demonstrated frequent hypermethylation
of various genes in urogenital cancers. In addition, the advent of
real-time PCR techniques for the quantification of methylation
levels has disclosed stage-dependent differences in the methylation
levels of the individual genes, as shown for RASSF1A and DAPK-1
in TCC of the upper urogenital tract (Catto et al, 2005). Moreover,
a few publications, pointing to findings for the DAPK-1 gene, have
postulated that the methylation frequency or level correlates with
the biological behaviour of the tumour disease (Tada et al, 2002;
Catto et al, 2005). In RCC, various methylation panels have been
presented with the highest methylation frequency of 45% for
RASSF1A, and the g-catenin gene has also been found to correlate
with a poorer prognosis (Dulaimi et al, 2004; Breault et al, 2005).
The role of APAF-1 methylation and its inactivation have been
described in malignant melanoma and human leukaemia cell lines.
Apoptotic protease activating factor-1 inactivation by promoter
methylation was suggested as a factor responsible for the inability
of cells to undergo apoptosis (Jia et al, 2001; Soengas et al, 2001).
DAPK-1 is a serine/threonine kinase widely expressed in normal
tissue. However, it seems to be epigenetically silenced by promoter
hypermethylation, as shown in a variety of cancers, including
gastrointestinal, head and neck, and small cell lung cancers and
B-cell lymphomas (Kissil et al, 1997; Sanchez-Cespedes et al, 2000;
Kim et al, 2001; Chan et al, 2005). The imbalance between pro- and
anti-apoptotic factors may lead to accumulation of transforming
mutations and resistance or decreased sensitivity to anticancer
treatment, as shown for APAF-1 inactivation in human leukaemic
cells or DAPK-1 inactivation in non-small cell lung cancer cells (Jia
et al, 2001; Tang et al, 2004).
Comparing the results obtained from quantitative methylation
analysis of the APAF-1 gene disclosed a high frequency of APAF-1
methylation. In fact, it occurred in nearly all the bladder and
kidney tumour samples investigated. Nevertheless, methylation
was also found in normal tissue, though at a lower frequency.
Using the NIM enabled us to differentiate not only between benign
methylated tissue and malignant tissue but also between lower and
higher tumour stages, as NIM levels increased with local tumour
progression in TCC. This was also the case in RCC, where tumour
characteristics like size and differentiation, but not the nodal
status, differed according to the specific APAF-1 NIM levels. Thus,
APAF-1 methylation levels can help to differentiate between
specific tumour stages in TCC and RCC. Death-associated protein
kinase-1 methylation was more frequent in malignant than in
benign tissue but did not correlate with a higher tumour stage or
differentiation grade. Nevertheless, we found a higher frequency of
DAPK-1 methylation in TCC and RCC in a larger cohort than in
previous reports (Tada et al, 2002; Wethkamp et al, 2006). In
addition, quantification revealed very heterogeneous methylation
levels. No significantly higher methylation levels were detected in
muscle-invasive TCC or node-positive RCC. Therefore, DAPK-1
methylation may not be a prerequisite for a more aggressive
tumour phenotype. In a nonquantitative analysis, Tada et al,
observed a DAPK-1 methylation frequency of 29% in TCC and
found that the recurrence rate correlated with DAPK-1 methylation
in a small cohort of 55 patients (Tada et al, 2002). They postulated
downregulation of DAPK-1 by hypermethylation, as immunohis-
tochemical staining was negative in tumour samples with DAPK-1
methylation. Interestingly, Wethkamp et al (2006), could not
detect methylation of the DAPK-1 gene in RCC when nonquanti-
tative analysis was performed in a small set of 10 patients.
Moreover, they also found persistent DAPK-1 mRNA expression in
a larger cohort of 72 patients with RCC. This suggests post-
translational inactivation, as in vitro studies in 11 RCC cell lines
demonstrated basal DAPK-1 activity in only one cell line despite
the detection of DAPK-1 mRNA expression (Wethkamp et al,
2006).
Cheng et al (2004a) previously reported growth-inhibitory
effects of zebularine in different human cancer cell lines, including
T24, a more advanced TCC cell line of the bladder. Moreover,
zebularine has been proved to be effective against the development
of murine T-cell lymphoma with complete lack of toxicity
(Herranz et al, 2006). The objective of our study was not only to
confirm the effectivity of demethylating agents in growth
retardation but also to find possible differences in the treatment
response of TCC or RCC cell lines, especially those belonging to a
more or less aggressive phenotype. Our data demonstrate for the
first time, that both 5-Aza-CdR and zebularine are effective growth
inhibitors in non-advanced as well as advanced TCC and RCC cell
lines. In TCC, 5-Aza-CdR achieved equal growth inhibition in RT4
and T24 cell lines, which we regard as secondary to its highly toxic
effects. Compared to 5-Aza-CdR, zebularine resulted in the same
percentage prolongation of the DT in the T24 cell line (79.8 vs
79.6%) but not in the RT4 cell line (66.4 vs 17.5%). This may be
due to the long DT (80h) of RT4, treatment effects becoming
visible after more than 7 days. Another explanation could be the
relative resistance of the p53 wild-type RT4 cells to demethylating
zebularine treatment, which would necessitate higher doses for
equal effectiveness. Demethylating agents are also effective for
growth inhibition in RCC cell lines. According to our data,
zebularine was an even more effective growth inhibitor than 5-
Aza-CdR in the p53 mutated (105.9 vs 131.8%) and the p53 wild-
type cell line (21.9 vs 54.6%). Growth-inhibitory effects of
Table 4 RGE of APAF-1 and DAPK-1 mRNA in RCC cell lines A498,
ClearCa-5, and TCC cell lines RT4, T24 after treatment with PBS, 5-AZA-
CdR (2 10




Cell line PBS 5-AZA ZEB PBS 5-AZA ZEB
A498
Median 159 410 139 60 29 58
Mean 164 420 139 60 30 58
STD 24.3 76.7 7.5 2.7 4.4 6.2
P-value* 0.002 0.09 0.0006 0.5
CCa-5
Median 108 163 133 11 19 20
Mean 110 164 135 11 18 20
STD 14.9 10.2 7.3 3.2 10.3 0.7
P-value* 0.003 0.01 0.006 0.007
RT4
Median 66 360 65 3 35 5
Mean 65 358 67 3 36 5
STD 2.1 14.3 7.6 0.7 3.8 1.2
P-value* 0.0001 0.4 0.0002 0.2
T24
Median 188 386 240 0.04 0.5 0.2
Mean 188 386 240 0.04 0.5 0.2
STD 16 5.3 11.1 0.008 0.04 0.01
P-value* 0.0001 0.004 0.0002 0.0001
APAF¼apoptotic activating factor protein; DAPK¼death-associated protein kinase;
PBS¼phosphate-buffered saline; RGE¼relative gene expression; STD¼standard
deviation; ZEB¼zebularine. *¼Comparison between PBS-treated and 5-AZA-CdR-
or zebularine-treated cells using paired Student’s t-test.
Methylation of APAF-1 and DAPK-1
F Christoph et al
1705



















szebularine may be multifactorial, as its DNA and RNA incorpora-
tion has been described (Ben-Kasus et al, 2005). Microarray
experiments have shown increased activation of cancer-related
antigens secondary to zebularine treatment, which could result in
augmented presentation of cell surface antigens (Cheng et al,
2004a,b). Especially in RCC, the combination regimen of
zebularine followed by immunotherapy could be a promising
treatment option, because it preferentially targets cancer cells,
shows activity in vitro as well as in experimental animals, and can
be orally administered (Marquez et al, 2005). We were able to
confirm the observations reported by Fu et al (2003) who
previously demonstrated upregulation of mRNA expression of
APAF-1 in human leukaemia cell lines after exposure to 5-Aza-
CdR. However, the reason for the unchanged mRNA expression of
APAF-1 and DAPK-1 after zebularine treatment in the p53 wild-
type cell lines A498 and RT4 is not clear. Zebularine has been
shown to be selective towards cancer cells, but is eventually less
effective in early stage or less aggressive subtypes to demethylate
and subsequently re-express specific, for example tumour
suppressor genes such as APAF-1 (Fu et al, 2003; Cheng et al,
2004b). It is also not evident, why the unmethylated DAPK-1 gene
was re-expressed in the p53-mutated cell lines after exposure to
5-Aza-CdR and zebularine or why 5-Aza-CdR upregulated its
expression in RT4 but downregulated its expression in A498 cell
lines. Global genome wide effects of these demethylating agents
might influence yet unknown regulators of the DAPK-1 gene,
which could be responsible for the effects observed. Therefore,
genome-wide analysis could help to further elucidate what is
responsible for this differences in regulation of mRNA expression
of DAPK-1. Moreover, subsequent western blot analysis will have
to determine whether there is a correlation between mRNA and
protein expression of the APAF-1 gene. This was not the case in the
human leukaemia cell lines studied by Fu et al (2003) which points
to post-transcriptional regulation of APAF-1 protein expression.
In conclusion, our data present APAF-1, a gene frequently
methylated in TCC of the bladder and RCC. The APAF-1
methylation level varies according to the tumour stage in TCC of
the bladder. In RCC, APAF-1 methylation levels depend on specific
characteristics such as tumour size or tumour differentiation.
Novel demethylating agents seem to be effective for growth
retardation not only in TCC but also in RCC cell lines. Thus, the
stability and minimal toxicity of the demethylating agent
zebularine renders it a promising candidate for epigenetic therapy
in RCC and TCC of the bladder.
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